These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2 files

Synthesis and Preclinical Evaluation of [18F]PF04217903, a Selective MET PET Tracer

submitted on 15.10.2020, 11:33 and posted on 16.10.2020, 06:32 by Vegard Torp Lien, Emily Hauge, Syed Nuruddin, Jo Klaveness, Dag Erlend Olberg

The tyrosine kinase MET (hepatocyte growth factor receptor) is abnormally activated in a wide range of cancers and is often correlated with a poor prognosis. Precision medicine with positron emission tomography (PET) can potentially aid in the assessment of tumor biochemistry and heterogeneity, which can prompt the selection of the most effective therapeutic regimes. The selective MET inhibitor PF04217903 (1) formed the basis for a bioisosteric replacement to the deoxyfluorinated analogue [18F]2, intended as a PET tracer for MET. [18F]2 could be synthesized with a “hydrous fluoroethylation” protocol in 6.3 ± 2.6% radiochemical yield and a molar activity of >50 GBq/µmol. In vitro autoradiography indicated that [18F]2 specifically binds to MET in PC3 tumor tissue, and in vivo biodistribution in mice showed predominantly a hepatobiliary excretion along with a low retention of radiotracer in other organs.


Email Address of Submitting Author


University of Oslo



ORCID For Submitting Author


Declaration of Conflict of Interest

No conflict of interest


Logo branding